<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662789</url>
  </required_header>
  <id_info>
    <org_study_id>IronIC</org_study_id>
    <nct_id>NCT03662789</nct_id>
  </id_info>
  <brief_title>Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients</brief_title>
  <acronym>IronIC</acronym>
  <official_title>Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency is prevalent in heart transplant recipients, and may be associated with&#xD;
      reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous&#xD;
      iron isomaltoside on exercise capacity, muscle strength, cognition and quality of life in&#xD;
      iron-deficient heart transplant recipients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency is prevalent in patients with heart failure. Iron deficiency is associated&#xD;
      with a worse prognosis, and randomised controlled trials have shown that correction of iron&#xD;
      deficiency with intravenous iron therapy improves functional capacity, quality of life, and&#xD;
      6-minute walk distance. Current guidelines therefore recommend intravenous iron substitution&#xD;
      in patients with heart failure with reduced ejection fraction and iron deficiency.&#xD;
      Intravenous iron is more effective, better tolerated, and improves quality of life to a&#xD;
      greater extent than oral iron supplements. In the IRONOUT HF trial, in which 225 patients&#xD;
      with systolic heart failure were randomised to oral iron supplement or placebo, there was no&#xD;
      effect on oxygen uptake, 6-minute walk distance, or quality of life. The authors attributed&#xD;
      the negative results to the minimal effect on iron stores, suggesting that oral iron does not&#xD;
      adequately replenish iron stores in patients with heart failure.&#xD;
&#xD;
      Cardiac allograft recipients resemble patients with heart failure in many respects. Prior to&#xD;
      transplantation, and in some instances after heart transplantation, they have had overt heart&#xD;
      failure. Moreover, due to the immunologic challenge posed by the allograft, and their&#xD;
      susceptibility to infection due to immunosuppressive treatment, cardiac allograft recipients&#xD;
      have low-grade inflammation. This low-grade inflammation makes it difficult to interpret iron&#xD;
      stores, and results in dysregulated iron metabolism.&#xD;
&#xD;
      There have been no studies to assess the effect of intravenous iron therapy in heart&#xD;
      transplant recipients who have iron deficiency. There is reason to believe that a liberal&#xD;
      definition of iron deficiency should be used in cardiac allograft recipients, and the&#xD;
      investigators have elected to use the well-established definition used in patients with heart&#xD;
      failure: serum ferritin &lt; 100 µg/l or ferritin between 100 and 300 µg/l in combination with a&#xD;
      transferrin saturation &lt; 20 %. Because oral iron supplement is less effective then&#xD;
      intravenous iron in general, and in patients with heart failure in particular, the&#xD;
      investigators assume that oral iron supplement is inadequate in heart transplant recipients.&#xD;
      the investigators have designed the IronIC trial to assess the effect of intravenous iron&#xD;
      isomaltoside on exercise capacity, muscle strength, cognition and quality of life in&#xD;
      iron-deficient heart transplant recipients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo controlled, parallel group, double blind design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Opaque envelopes, infusion administered by third party, concealed infusion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Oxygen Consumption</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>The primary endpoint will be the baseline-adjusted between-group difference in peak oxygen consumption as measured on a treadmill exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Iron Deficiency</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>The number of patients with absolute or functional iron deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Baseline-adjusted muscle strength as measured by a hand-grip dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: SF-36, Physical Component Summary (PCS)</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>The between-group difference in baseline-adjusted NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Troponin T (TnT)</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>The between-group difference in baseline-adjusted TnT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: SF-36, Mental Component Summary (MCS)</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Heart Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside 1000</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <other_name>Monofer B03AC-</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo: NaCl 0,9%</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cardiac allograft.&#xD;
&#xD;
          -  Presentation at least one year after heart transplantation.&#xD;
&#xD;
          -  Iron deficiency defined as serum ferritin &lt; 100 µg/l or ferritin between 100 and 300&#xD;
             µg/l in combination with a transferrin saturation &lt; 20 %.&#xD;
&#xD;
          -  Age between 18 and 80 years.&#xD;
&#xD;
          -  Informed consent obtained and documented according to Good Clinical Practice (GCP),&#xD;
             and national/regional regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaemia (Haemoglobin &lt; 100 mg/l)&#xD;
&#xD;
          -  Haemochromatosis&#xD;
&#xD;
          -  Haemosiderosis&#xD;
&#xD;
          -  Porphyria cutanea tarda&#xD;
&#xD;
          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells&#xD;
&#xD;
          -  Decompensated liver disease (Child-Pugh score 7 or higher)&#xD;
&#xD;
          -  End-stage renal failure, i.e. estimated glomerular filtration rate &lt; 15 ml/min or on&#xD;
             renal replacement therapy&#xD;
&#xD;
          -  Planned cardiac surgery or angioplasty within 6 months&#xD;
&#xD;
          -  Planned major surgery within 6 months&#xD;
&#xD;
          -  Medical history of unresolved cancer (except for basal cell carcinoma)&#xD;
&#xD;
          -  Treatment with systemic steroids more than the equivalent of 10 mg Prednisone/day at&#xD;
             the time of informed consent or change in dosage of thyroid hormones within 6 weeks&#xD;
             prior to informed consent&#xD;
&#xD;
          -  Any uncontrolled endocrine disorder except type 2 diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  On erythropoietin analogues&#xD;
&#xD;
          -  Known sensitivity or intolerance to iron isomaltoside or other parenteral iron&#xD;
             preparations&#xD;
&#xD;
          -  Intravenous iron supplement within 6 months prior to inclusion&#xD;
&#xD;
          -  On oral iron substitution (unless the subject agrees to stop treatment prior to&#xD;
             randomisation)&#xD;
&#xD;
          -  Ongoing rejections or infections&#xD;
&#xD;
          -  Alcohol or drug abuse within 3 months of informed consent that would interfere with&#xD;
             trial participation or any ongoing condition leading to decreased compliance with&#xD;
             study procedures or study drug intake&#xD;
&#xD;
          -  Intake of an investigational drug in another trial within 30 days prior to intake of&#xD;
             study medication in this trial or participating in another trial involving an&#xD;
             investigational drug and/or follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Gullestad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo university Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Brautaset Englund KV, Østby CM, Rolid K, Gude E, Andreassen AK, Gullestad L, Broch K. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. J Heart Lung Transplant. 2021 May;40(5):359-367. doi: 10.1016/j.healun.2021.01.1390. Epub 2021 Jan 23.</citation>
    <PMID>33612360</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <results_first_submitted>February 25, 2021</results_first_submitted>
  <results_first_submitted_qc>April 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Gullestad</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Heart transplant</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Intravenous iron supplement</keyword>
  <keyword>Peak oxygen consumption</keyword>
  <keyword>Cardiopulmonary exercise test</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Muscle strength</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03662789/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03662789/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iron Isomaltoside 1000</title>
          <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">Baseline</participants>
                <participants group_id="P2" count="50">Baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47">Follow-up at 6 months</participants>
                <participants group_id="P2" count="43">Follow-up at 6 months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not perform treadmill test</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iron Isomaltoside 1000</title>
          <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="15"/>
                    <measurement group_id="B2" value="55" spread="14"/>
                    <measurement group_id="B3" value="55" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak oxygen consumption</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="7.3"/>
                    <measurement group_id="B2" value="22.3" spread="6.0"/>
                    <measurement group_id="B3" value="23.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Oxygen Consumption</title>
        <description>The primary endpoint will be the baseline-adjusted between-group difference in peak oxygen consumption as measured on a treadmill exercise test</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Oxygen Consumption</title>
          <description>The primary endpoint will be the baseline-adjusted between-group difference in peak oxygen consumption as measured on a treadmill exercise test</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="6.6"/>
                    <measurement group_id="O2" value="22.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Deficiency</title>
        <description>The number of patients with absolute or functional iron deficiency</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Iron Deficiency</title>
          <description>The number of patients with absolute or functional iron deficiency</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Strength</title>
        <description>Baseline-adjusted muscle strength as measured by a hand-grip dynamometer</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Strength</title>
          <description>Baseline-adjusted muscle strength as measured by a hand-grip dynamometer</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="13"/>
                    <measurement group_id="O2" value="38" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life: SF-36, Physical Component Summary (PCS)</title>
        <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life: SF-36, Physical Component Summary (PCS)</title>
          <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
          <units>t-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="42" upper_limit="55"/>
                    <measurement group_id="O2" value="45" lower_limit="37" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)</title>
        <description>The between-group difference in baseline-adjusted NT-proBNP</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)</title>
          <description>The between-group difference in baseline-adjusted NT-proBNP</description>
          <units>ng/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421" lower_limit="134" upper_limit="807"/>
                    <measurement group_id="O2" value="349" lower_limit="237" upper_limit="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Troponin T (TnT)</title>
        <description>The between-group difference in baseline-adjusted TnT</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Troponin T (TnT)</title>
          <description>The between-group difference in baseline-adjusted TnT</description>
          <units>ng/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="8.0" upper_limit="25.8"/>
                    <measurement group_id="O2" value="15.0" lower_limit="8.0" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life: SF-36, Mental Component Summary (MCS)</title>
        <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
        <time_frame>6 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life: SF-36, Mental Component Summary (MCS)</title>
          <description>Baseline-adjusted quality of life as assessed with the 36-item short form survey (SF-36), which measures each of the following 8 health domains: 1= general health, 2= physical function, 3= role physical, 4= bodily pain, 5= vitality, 6= social function, 7= role emotional, 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represented higher level of functioning. Two norm-based sum scores, the physical and the mental component summaries with a mean of 50±10, were generated from the eight scale scores using a T-score transformation. Higher scores represented higher level of functioning.</description>
          <units>t-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="49" upper_limit="60"/>
                    <measurement group_id="O2" value="53" lower_limit="48" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse events were registered at the follow up at 6 months for all participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Iron Isomaltoside 1000</title>
          <description>The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (&quot;on-label&quot; treatment).&#xD;
Iron Isomaltoside 1000: Intravenous infusion</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%&#xD;
Placebo: NaCl 0,9%: Intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ST-elevation myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Deceased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyreosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelitiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <description>Worsening of diabetes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Worsening of chronic condition. Did not require hospital admission.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Spotty facial discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Generalized Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Local rash</sub_title>
                <description>Left ankle</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lars Gullestad</name_or_title>
      <organization>Oslo University Hospital</organization>
      <phone>0047 97644772</phone>
      <email>lars.gullestad@medisin.uio.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

